tm logo
DIAFERT
Dead/Abandoned
ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE

failure to respond or late response

on 17 Aug 2020

Last Applicant/ Owned by

Rue de Travail 16

Grâce-Hollogne

BE

4460

Serial Number

88339989 filed on 14th Mar 2019

Registration Number

N/A

Correspondent Address

Matthew O. Brady

ALLERGAN, INC.

2525 Dupont Drive

Irvine, CA, 92612

Filing Basis

1. intent to use

2. intent to use current

Disclaimer

NO DATA

DIAFERT

Pharmaceutical preparations used in connection with anti-aging, namely, pharmaceutical preparations for use in the treatment of glabellar lines, facial wrinkles, facial asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatories, anti-infectives, antiRead More

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations used in connection with anti-aging, namely, pharmaceutical preparations for use in the treatment of glabellar lines, facial wrinkles, facial asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma agents and decongestants; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing pharmaceutical preparations; pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; pharmaceutical preparations and medicines for the treatment of sensory organ disorders; pharmaceutical preparations and medicines for the treatment of central nervous system disorders; pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; pharmaceutical preparations and medicines for the treatment of circulatory system disorders; pharmaceutical preparations and medicines for the treatment of cardiovascular diseases and high blood pressure; pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; pharmaceutical preparations for supporting, encouraging and promoting bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; antibiotics; antifungal preparations; antivirals; antiprotozoans, namely, pharmaceutical preparations for treating infections caused by protozoa; pharmaceutical preparations for the prevention and treatment of bacterial infections; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS (central nervous system) disorders, neurological disorders, neurodegenerative disorders and depression; neuroprotective agent, namely, pharmaceutical preparations to help prevent or reduce damage to the brain or spinal cord; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents, namely, pharmaceutical preparations for dilating blood vessels; pharmaceutical preparations for the treatment of hypothyroidism; pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenating creams, rehydrating creams and lotions for the face and body, excluding iron preparations for pharmaceutical use and iron preparations as food supplements

Mark Details


Serial Number

No 88339989

Mark Type

No Service/Collective Mark

Attorney Docket Number

No

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
17th Aug 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
17th Aug 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
04th Feb 2020NOTIFICATION OF FINAL REFUSAL EMAILED
04th Feb 2020FINAL REFUSAL E-MAILED
04th Feb 2020FINAL REFUSAL WRITTEN
13th Jan 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
13th Jan 2020TEAS/EMAIL CORRESPONDENCE ENTERED
09th Jan 2020ASSIGNED TO LIE
17th Dec 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
13th Dec 2019NON-FINAL ACTION E-MAILED